Etoposide

Generic Name
Etoposide
Brand Names
Etopophos, Toposar, Vepesid
Drug Type
Small Molecule
Chemical Formula
C29H32O13
CAS Number
33419-42-0
Unique Ingredient Identifier
6PLQ3CP4P3
Background

A semisynthetic derivative of podophyllotoxin that exhibits antitumor activity. Etoposide inhibits DNA synthesis by forming a complex with topoisomerase II and DNA. This complex induces breaks in double stranded DNA and prevents repair by topoisomerase II binding. Accumulated breaks in DNA prevent entry into the mitotic phase of cell division, and lead to cell death. Etoposide acts primarily in the G2 and S phases of the cell cycle.

Indication

For use in combination with other chemotherapeutic agents in the treatment of refractory testicular tumors and as first line treatment in patients with small cell lung cancer. Also used to treat other malignancies such as lymphoma, non-lymphocytic leukemia, and glioblastoma multiforme.

Associated Conditions
Acute Lymphoblastic Leukaemias (ALL), Acute Myeloid Leukemia, Advanced Hodgkin's Lymphoma, Ewing's Sarcoma, Gestational Trophoblastic Neoplasia, Merkel cell cancer, Multiple Myeloma (MM), Neuroblastoma (NB), Neuroendocrine Tumors, Non-Hodgkin's Lymphomas, Non-Small Cell Lung Cancer (NSCLC), Osteosarcoma, Ovarian Cancer, Prostate Cancer, Retinoblastoma, Small Cell Lung Cancer (SCLC), Wilms' tumor, Locally advanced Thymoma, Metastatic Thymic Cancer, Refractory Sarcoma, Refractory Testicular cancer
Associated Therapies
-
Clinical Trials
Related News

Use Of A Response-Adapted Ruxolitinib-Containing Regimen For The Treatment Of Hemophagocytic Lymphohistiocytosis

First Posted Date
2020-09-16
Last Posted Date
2024-08-28
Lead Sponsor
St. Jude Children's Research Hospital
Target Recruit Count
62
Registration Number
NCT04551131
Locations
🇺🇸

University of Texas Southwestern Medical Center, Dallas, Texas, United States

🇺🇸

John Hopkins University, Baltimore, Maryland, United States

🇺🇸

Texas Children's Hospital, Houston, Texas, United States

and more 10 locations

A Prospective Study Comparing Two Radiotherapy Dose/Fraction and Omitting CTVs of the Primary Tumor in Limited SCLC

First Posted Date
2020-09-10
Last Posted Date
2020-09-10
Lead Sponsor
Zhejiang Cancer Hospital
Target Recruit Count
300
Registration Number
NCT04543890
Locations
🇨🇳

Zhejiang Cancer Hospital, Hangzhou, Zhejiang, China

Donor Stem Cell Transplant After Chemotherapy for the Treatment of Recurrent or Refractory High-Risk Solid Tumors in Pediatric and Adolescent-Young Adults

First Posted Date
2020-08-28
Last Posted Date
2024-10-26
Lead Sponsor
M.D. Anderson Cancer Center
Target Recruit Count
40
Registration Number
NCT04530487
Locations
🇺🇸

M D Anderson Cancer Center, Houston, Texas, United States

Chemotherapy and Donor Stem Transplant for the Treatment of Patients With High Grade Brain Cancer

First Posted Date
2020-08-21
Last Posted Date
2024-10-26
Lead Sponsor
M.D. Anderson Cancer Center
Registration Number
NCT04521946

Thoracic Radiotherapy Plus Maintenance Durvalumab After First Line Carboplatin and Etoposide Plus Durvalumab in Extensive-stage Disease Small Cell Lung Cancer (ED-SCLC).

First Posted Date
2020-07-16
Last Posted Date
2023-09-13
Lead Sponsor
Swiss Group for Clinical Cancer Research
Target Recruit Count
46
Registration Number
NCT04472949
Locations
🇨🇭

Spital Männedorf, Männedorf, Switzerland

🇨🇭

Regionalspital Thun, Thun, Switzerland

🇨🇭

IOSI Ospedale Regionale di Bellinzona e Valli, Bellinzona, Switzerland

and more 11 locations

Sirolimus in Combination With Metronomic Chemotherapy in Children With High-Risk Solid Tumors

First Posted Date
2020-07-14
Last Posted Date
2024-11-13
Lead Sponsor
Emory University
Target Recruit Count
50
Registration Number
NCT04469530
Locations
🇺🇸

Children's Healthcare of Atlanta, Atlanta, Georgia, United States

🇺🇸

Aflac Cancer & Blood Disorders Centers, Atlanta, Georgia, United States

🇺🇸

Texas Children's Cancer Center, Houston, Texas, United States

and more 2 locations

Lenalidomide in Combination With R-DA-EPOCH in Patients With Untreated DLBCL With MYC Rearrangement

First Posted Date
2020-06-16
Last Posted Date
2020-06-16
Lead Sponsor
The First Affiliated Hospital with Nanjing Medical University
Target Recruit Count
81
Registration Number
NCT04432714
Locations
🇨🇳

The first Affiliated Hospital Of Nanjing Medical University(JiangSu Province Hospital), Nanjing, Jiangsu, China

A Study Evaluating The Safety, Tolerability, Pharmacokinetics, And Efficacy Of Venetoclax In Combination With Atezolizumab, Carboplatin, And Etoposide In Participants With Untreated Extensive-Stage Small Cell Lung Cancer (ES-SCLC).

First Posted Date
2020-06-09
Last Posted Date
2021-11-08
Lead Sponsor
Hoffmann-La Roche
Target Recruit Count
2
Registration Number
NCT04422210
Locations
🇰🇷

Severance Hospital, Yonsei University Health System, Seoul, Korea, Republic of

🇺🇸

Emory University, Atlanta, Georgia, United States

🇩🇰

Rigshospitalet; Onkologisk Klinik, København Ø, Denmark

and more 2 locations

GPED Regimen for Relapsed/Refractory or Advanced ENKTCL

First Posted Date
2020-05-28
Last Posted Date
2020-05-28
Lead Sponsor
Beijing Tongren Hospital
Target Recruit Count
29
Registration Number
NCT04405375
Locations
🇨🇳

Beijing Tongren Hospital, Beijing, China

Study of Pembrolizumab With Concurrent Chemoradiation Therapy Followed by Pembrolizumab With or Without Olaparib in Stage III Non-Small Cell Lung Cancer (NSCLC) (MK-7339-012/KEYLYNK-012)

First Posted Date
2020-05-08
Last Posted Date
2024-11-19
Lead Sponsor
Merck Sharp & Dohme LLC
Target Recruit Count
870
Registration Number
NCT04380636
Locations
🇺🇸

Torrance Memorial Physician Network / Cancer Center ( Site 0093), Torrance, California, United States

🇺🇸

UCLA Hematology/Oncology - Santa Monica ( Site 0013), Los Angeles, California, United States

🇺🇸

Miami VA Healthcare System ( Site 0024), Miami, Florida, United States

and more 202 locations
© Copyright 2024. All Rights Reserved by MedPath
HomeTerms & ConditionsPrivacy Policy